Kura Oncology announced encouraging Phase 1A results for its drug combination darlifarnib plus cabozantinib in advanced kidney cancer patients. The data show high response rates and favorable progression-free survival, suggesting a significant potential improvement over existing therapies and supporting further clinical development.
Kura Oncology released updated Phase 1A results from its FIT-001 clinical trial, highlighting encouraging and durable clinical activity of darlifarnib combined with cabozantinib in cabozantinib-naïve patients with advanced clear cell renal cell carcinoma (ccRCC). The reported response rates up to 50% and a median progression-free survival (PFS) of 13 months compare favorably with historical outcomes for existing monotherapies, indicating a potentially superior treatment option. This positive data is a significant catalyst for Kura Oncology (KURA), as it validates their drug candidate and supports its potential to enhance VEGFR-targeted therapies. For traders, this presents a short-term opportunity for KURA stock appreciation due to increased investor confidence and long-term potential if subsequent trials confirm these findings and lead to market approval, while also potentially impacting competitors in the ccRCC treatment space like Exelixis (EXEL), which manufactures cabozantinib.